ArticleInternational journal of nanomedicine2025
Development of a Ferritin-Based Nano-Allergen and Its Immunological Effects in vitro and in vivo.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mechanisms and Biomedical Applications of Ferritin Nanocages: A Comprehensive Review of Self-Assembly, Engineering, and Multifunctional Delivery Platforms.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We aimed to develop recombinant allergens on the nanoscale by using self-assembly property of ferritin and to investigate their immune response and protective effect. Methods: The cDNA encoding Ftn-Blo t 2 was synthesized and cloned into pET-21a (+) vector, then expressed in Results: The average diameter of rFtn and rFtn-Blo t 2 particles are (11.24 ± 1.31) nm and (16.00 ± 1.59) nm. The IgE- binding rates of rFtn-Blo t 2 and rBlo t 2 were 62.5% (15/24) and 58.3% (12/24), respectively. The expressions of IL-25, IL-33, and TSLP increased by 3.29, 3.43, and 2.22 folds after the addition of rFtn-Blo t 2 in co-culture with BEAS-2B. Mice challenged with rBlo t 2 had lower levels of cytokines IL-13 and IL-4 but higher levels of IFN-γ and TGF-β in alveolar lavage fluid compared to controls (p < 0.05). HE staining showed that compared with rBlo t 2 group, the inflammation level in lung tissue of rFtn-Blo t 2 group was reduced. Discussion: A nano-scale allergen was successfully developed, providing a concept, a platform, and a paradigm for the construction of nano-scale allergens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.